Patents
(WO 2013/071418) METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREFORE. 23.05.2013 C07F 9/6584 PCT/CA2012/001064 PHENOMENOME DISCOVERIES INC.
A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.
(WO 2013/071411) METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD. 23.05.2013 C07C 57/03 PCT/CA2012/001053 PHENOMENOME DISCOVERIES INC.
A method for preparing 13C labeled docosahexaenoic acid (DHA) represented by Formula A: The method comprises the conversion of 2-pentyn-l-ol to 13C labeled DHA by reaction with propargyl alcohol, 13C labeled propargyl alcohol and methyl pent-4-ynoate. The various steps involved include tosylation, coupling, bromination, selective hydrogenation and ester hydrolysis to obtain the final product.
(WO 2013/071413) METHODS FOR THE SYNTHESIS OF 13C LABELED LODOTRIDECANE AND USE AS A REFERENCE STANDARD. 23.05.2013 C07C 19/07PCT/CA2012/001055 PHENOMENOME DISCOVERIES INC.
A method for preparing 13C labeled iodotridecane represented by Formula A. The method comprises the conversion of 13C labeled propargyl alcohol to 13C labeled iodotridecane via alkylation of propargyl alcohol with iododecane.
(WO 2013/071412) METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN. 23.05.2013 C07F 9/6584 PCT/CA2012/001054 PHENOMENOME DISCOVERIES INC.
A method for preparing 13C labeled plasmalogens as represented by Formula B:-The method involves producing a 13C labeled cyclic plasmalogen precursor of Formula A, and conversion of the precursor to a plasmalogen of Formula B. These plasmalogens may potentially be useful in the determination of both the mechanism of action as well as the fate of plasmalogens in the body.
(WO 2011/011882) HYDROXY FATTY ACID COMPOUNDS AND USES THEREOF FOR DISEASE TREATMENT AND DIAGNOSIS. 03.02.2011 C07C 59/42 PCT/CA2010/001179 PHENOMENOME DISCOVERIES INC.
A compound of formula (I): wherein R represents a hydroxy substituted C24 - C40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.
(WO 2010/071988) PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF AGING MEDIATED BY PLASMALOGEN DEFICIENCY. 01.07.2010 C07D 339/04 PCT/CA2009/001853 PHENOMENOME DISCOVERIES INC.
Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
(WO 2009/012595) METHODS FOR THE DIAGNOSIS, RISK ASSESSMENT, AND MONITORING OF AUTISM SPECTRUM DISORDERS 29.01.2009 G01N 33/48 PCT/CA2008/001366 PHENOMENOME DISCOVERIES INC.
Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.
(WO 2008/124916) METHODS FOR THE DIAGNOSIS AND RISK ASSESSMENT OF PLASMALOGEN DEFICIENCY MEDIATED DISEASES OF AGING 23.10.2008 G01N 33/48 PCT/CA2008/000659 PHENOMENOME DISCOVERIES INC.
The present invention relates to methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging. The present invention describes the relationship between plasmalogen biosynthesis dysfunction and the biochemical and clinical manifestations of age-related disorders. Specifically, the present invention describes an increased prevalence of colon cancer, prostate cancer, lung cancer, breast cancer, ovary cancer, kidney cancer, cognitive impairment and dementia in subjects suffering from adult onset plasmalogen biosynthesis disorder (AO-PBD).
(WO 2008/095275) METHODS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER’S TYPE 14.08.2008 A61K 31/232 PCT/CA2007/001472 PHENOMENOME DISCOVERIES INC.
The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT.
(WO 2008/095275) METHODS FOR THE TREATMENT OF ELEVATED CHOLESTEROL LEVELS (METHOD FOR LOWERING CHOLESTEROL). 14.08.2008 A61K 31/232 PCT/CA2007/001472 PHENOMENOME DISCOVERIES INC.
The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients.
(WO 2007/137410) BIOMARKERS USEFUL FOR DIAGNOSING MULTIPLE SCLEROSIS AND OTHER NEUROLOGICAL DISORDERS, AND METHODS THEREOF. 06.12.2007 C07C 59/62 PCT/CA2007/000932 PHENOMENOME DISCOVERIES INC.
The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis A method is also provided for the differential diagnosis of subjects afflicted with relapsing- remitting multiple sclerosis from secondary-progressive multiple sclerosis.
(WO 2007/098585) METHODS FOR THE DIAGNOSIS OF DEMENTIA AND OTHER NEUROLOGICAL DISORDERS 07.09.2007 C07F 9/09 PCT/CA2007/000313 PHENOMENOME DISCOVERIES INC.
The present invention is directed to a method for differentially diagnosing dementia or the risk of dementia in a patient. The method comprises obtaining a sample from the patient; analyzing the sample to obtain quantifying data for one or more than one metabolite marker; comparing the quantifying data for the one or more than one metabolite marker to corresponding data obtained from one or more than one reference sample; and using the comparison to differentially diagnose dementia or the risk of dementia. The method may also assist in assessing dementia or the risk of dementia in a patient. The present invention is also directed to metabolite markers and compounds useful in the present method.
(WO 2007/030948) METHOD AND APPARATUS FOR FOURIER TRANSFORM ION CYCLOTRON RESONANCE MASS SPECTROMETRY 22.03.2007 H01J 49/26 PCT/CA2006/001530 PHENOMENOME DISCOVERIES INC.
A novel method and apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS). The FTICR-MS apparatus has a pre-ICR mass separation and filtering device capable of receiving ionized molecules with a plurality of mass to charge (M/Z) sub-ranges. The pre-ICR mass separation and filtering device divides the ionized molecules into a plurality of smaller packets, each of the smaller packets is within one of the M/Z sub-ranges. A magnet in the FTICR-MS apparatus provides a controlled magnetic field. A plurality of ion cyclotron resonance (ICR) cells is arranged in series in the controlled magnetic field and operate independently. An ion trapping device connects the pre-ICR mass separation and filtering device, and stores one of the plurality of smaller packets, prior to sending it to one of the plurality of ICR cells.
(WO 2007/030928) METHODS FOR THE DIAGNOSIS OF COLORECTAL CANCER AND OVARIAN CANCER BY THE MEASUREMENT OF VITAMIN E-RELATED METABOLITES 22.03.2007 G01N 33/574 PCT/CA2006/001502 PHENOMENOME DISCOVERIES INC.
The present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively). The present invention describes the relationship between endogenous small molecules and CRC or OC. Specifically, the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. The present invention also relates to diagnostic markers identified in said method. The present invention relates to the underlying case and pre-symptomatic phases of CRC, the diagnosis of various stages and severity of CRC, the early detection of CRC, monitoring and diagnosing the effect of therapy on CRC and OC health states.
(WO 2003/081506) METHOD OF VISUALIZING NON-TARGETED METABOLOMIC DATA GENERATED FROM FOURIER TRANSFORM ION CYCLOTRON RESONANCE MASS SPECTROMETERS 02.10.2003 G06F 19/00 PCT/CA2003/000389 PHENOMENOME DISCOVERIES INC.
The invention can be summarized as follows. The present invention provides a method of displaying spectroscopic data comprising the steps of, i)obtaining spectroscopic data from a plurality of samples, each sample comprising one or more components wherein each component is characterized by an ordered pair (X,Y) of data comprising data element value X
and data element value Y, wherein X is a data element value, equivalent or directly proportional to the mass of the component, and Y is a data element value equivalent or directly proportional to the amount of the component; ii) identifying all unique components comprising a common data element value X in said samples; computing the average of all X therefrom; and determining the average and optionally, the standard deviation for all Y values from all ordered data pairs comprising a common X; iii) generating a data structure comprising an array of codable cells, each cell assigned a color or other identifiable characteristic based on the relationship of the amount of each unique component present in each of said samples in relation to a predetermined value or other characteristic of the spectroscopic data. Also disclosed are data structures comprising spectroscopic data.
(WO 2001/057518) METHOD OF NON-TARGETED COMPLEX SAMPLE ANALYSIS. 09.08.2001 H01J 49/42 PCT/CA2001/000111 YOL BOLSUM CANADA INC.
A method for non-targeted complex sample analysis which involves the following steps. A first step involves providing a database (16) containing identifying data of known molecules. A second step involves introducing a complex sample containing multiple unidentified molecules into a Fourier Transform Ion Cyclotron Mass Spectrometer (12) to obtain data regarding the molecules in the complex sample. A third step involves comparing the collected data regarding the molecules in the complex sample with the identifying data of known molecules in order to arrive at an identification through comparison of the molecules in the sample.